Takeda Pharmaceutical Company Limited today announced that Takeda has received notification from the U.S. FDA that the FDA extended the review of the New Drug Application for the fixed-dose combination (FDC) of alogliptin and ACTOS (pioglitazone HCl).
The details can be read here.
No comments:
Post a Comment